In the phase III ALEX trial, treatment naïve patients with stage IIIB or IV NSCLC with ALK rearrangement were randomly assigned to receive alectinib, a second generation ALK inhibitor or crizotinib, the current standard of care. This evidence concerns the gene ALK and non-small cell lung carcinoma.